Person who experienced the adverse event (patient)
| Event ID | CASE | I F COD | FOLL SEQ | IMAGE | EVENT DT | MFR DT | FDA DT | REPT COD | MFR NUM | MFR SNDR | AGE | AGE COD | GNDR COD | E SUB | WT | WT COD | REPT DT | OCCP COD | DEATH DT | TO MFR | CONFID | REPORTER COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4412869 | 4186209 | I | 4412869-5 | 20040706 | 20040713 | 20040727 | EXP | 2004-BP-05595BP | B.I. PHARMACEUTICALS INC. | 8 | YR | F | N | 20040726 | PH |
Drug(s) used by person
| Event ID | DRUG SEQ | ROLE COD | DRUGNAME | VAL VBM | ROUTE | DOSE VBM | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4412869 | 1005067220 | PS | CATAPRES | 1 | ORAL | 0.2 MG (0.1 MG, 1 TABLET BID), PO | D | D | 17407 | ||
| 4412869 | 1005090164 | SS | ADDERALL XR 10 | 1 | 20 MG | U | D |
Indications of drugs used
| Event ID | DRUG SEQ | INDI PT |
|---|---|---|
| 4412869 | 1005067220 | ATTENTION DEFICIT/HYPERACTIVITY DISORDER |
| 4412869 | 1005090164 | ATTENTION DEFICIT/HYPERACTIVITY DISORDER |
Outcome of event
| Event ID | OUTC COD |
|---|---|
| 4412869 | HO |
Reactions reported
| Event ID | PT |
|---|---|
| 4412869 | ELECTROCARDIOGRAM ABNORMAL |
| 4412869 | PO2 DECREASED |
| 4412869 | PSYCHIATRIC SYMPTOM |
| 4412869 | SKIN DISCOLOURATION |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | RPSR COD |
|---|---|
| 4412869 | HP |
Therapies reported
| Event ID | DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|
| 4412869 | 1005067220 | 20040707 | |||
| 4412869 | 1005090164 | 20040707 |